PMC:7377212 / 20423-21264
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T163 | 20-36 | CHEBI:35705;CHEBI:35705 | denotes | immunomodulatory |
T164 | 37-42 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
T165 | 73-88 | PR:000001137 | denotes | interleukin-1Ra |
T166 | 91-102 | DG_35 | denotes | tocilizumab |
T167 | 109-122 | PR:000001393 | denotes | interleukin-6 |
T168 | 141-151 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T169 | 185-193 | SP_7 | denotes | COVID-19 |
T170 | 495-504 | UBERON:0002048 | denotes | pulmonary |
T171 | 623-631 | SP_7 | denotes | COVID-19 |
T172 | 632-641 | UBERON:0002048 | denotes | pulmonary |
T173 | 724-735 | UBERON:0001004 | denotes | respiratory |
T174 | 769-777 | SP_7 | denotes | COVID-19 |
T69247 | 35-50 | CHEBI:35705;CHEBI:35705 | denotes | y drugs such as |
T20303 | 51-56 | CHEBI:23888;CHEBI:23888 | denotes | anaki |
T81754 | 87-93 | PR:000001137 | denotes | a), to |
T16643 | 96-107 | DG_35 | denotes | izumab (ant |
T55627 | 114-117 | PR:000001393 | denotes | leu |
T41646 | 142-152 | CHEBI:35222;CHEBI:35222 | denotes | nhibitors, |
T67111 | 186-193 | SP_7 | denotes | OVID-19 |
T31029 | 495-504 | UBERON:0002048 | denotes | pulmonary |
T56928 | 623-630 | SP_7 | denotes | COVID-1 |
T40668 | 631-640 | UBERON:0002048 | denotes | pulmonar |
T57506 | 723-734 | UBERON:0001004 | denotes | respirator |
T68575 | 768-776 | SP_7 | denotes | COVID-1 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T51 | 73-84 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
T52 | 109-122 | Body_part | denotes | interleukin-6 | http://purl.org/sig/ont/fma/fma264829 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
601 | 73-88 | Gene | denotes | interleukin-1Ra | Gene:3557 |
603 | 215-223 | Species | denotes | patients | Tax:9606 |
604 | 293-301 | Species | denotes | patients | Tax:9606 |
605 | 580-588 | Species | denotes | patients | Tax:9606 |
606 | 695-703 | Species | denotes | patients | Tax:9606 |
607 | 268-279 | Species | denotes | Aspergillus | Tax:746128 |
608 | 91-102 | Chemical | denotes | tocilizumab | MESH:C502936 |
609 | 185-193 | Disease | denotes | COVID-19 | MESH:C000657245 |
611 | 548-564 | Disease | denotes | cavitary disease | MESH:C566924 |
612 | 623-650 | Disease | denotes | COVID-19 pulmonary fibrosis | MESH:C000657245 |
613 | 724-744 | Disease | denotes | respiratory problems | MESH:D012818 |
614 | 769-777 | Disease | denotes | COVID-19 | MESH:C000657245 |
615 | 778-787 | Disease | denotes | infection | MESH:D007239 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T211 | 185-193 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T212 | 227-231 | Disease | denotes | CAPA | http://purl.obolibrary.org/obo/MONDO_0007163 |
T213 | 505-518 | Disease | denotes | aspergillosis | http://purl.obolibrary.org/obo/MONDO_0005657 |
T214 | 623-631 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T215 | 632-650 | Disease | denotes | pulmonary fibrosis | http://purl.obolibrary.org/obo/MONDO_0002771 |
T216 | 769-777 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T217 | 778-787 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T177 | 109-122 | http://purl.obolibrary.org/obo/PR_000001393 | denotes | interleukin-6 |
T178 | 538-539 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T179 | 568-569 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T303 | 37-42 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T304 | 91-102 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T305 | 141-151 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 134-151 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | kinase inhibitors |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T105 | 233-456 | Sentence | denotes | There is also an increased risk of Aspergillus exposure for patients who are treated in hospital wards or makeshift “hospital” facilities that do not meet ICU specifications for appropriate room ventilation and air changes. |
T106 | 457-651 | Sentence | denotes | It is also worth bearing in mind that pulmonary aspergillosis could develop into a chronic cavitary disease in a subset of patients, perhaps in those developing post-COVID-19 pulmonary fibrosis. |
T107 | 652-841 | Sentence | denotes | For these reasons, clinicians following up patients manifesting chronic respiratory problems following their primary COVID-19 infection should bear in mind longer term fungal complications. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T49 | 632-650 | Phenotype | denotes | pulmonary fibrosis | http://purl.obolibrary.org/obo/HP_0002206 |
T50 | 724-744 | Phenotype | denotes | respiratory problems | http://purl.obolibrary.org/obo/HP_0002795 |